Abstract 118P
Background
Gastrointestinal stromal tumors (GISTs) form the most common mesenchymal tumor of the gastrointestinal tract. The majority of GISTs are characterized by activating mutations in the KIT and PDGFRA genes (80 – 85 %). Approximately 10 – 15 % of adult (and 85 % pediatric) GISTs do not have detectable mutations in KIT or PDGFRA genes (KIT/PDGFRA non-mutated GISTs). KIT/PDGFRA non-mutated GISTs are a very heterogeneous group of tumors with alteration in SDH (SDH-deficient GIST accounting for approximately 20–40% of all KIT/PDGFRA no-mutated GISTs), BRAF, NF1, KRAS genes or FGFR1::TACC1, ETV6::NTRK3 fusions.
Methods
We examine the patient's DNA and RNA using Sanger sequencing, High-Resolution Melting, Allele-Specific PCR, and NGS methods to identify mutations of selected genes.
Results
We detected primary mutations in KIT and PDGFRA genes in 84 % of samples (337 samples). The presence of secondary mutations we demonstrated in 17 patients (157 analyzed patients, 11 %) with the progression of the disease. We confirmed significant intratumor and also intertumor heterogeneity of secondary mutations. In the group of KIT/PDGFRA non-mutated GISTs (56 samples), we identify defects in the SDH complex subunits (12 samples, 21 %), mutations in the BRAF (2 samples, 3.5 %) and NF1 (1 sample, 2 %) genes, and alterations in the AKT1 (1 sample, 2 %) and ATR (1 sample, 2 %) genes.
Conclusions
Determination of the GISTsmolecular subtype is very important considering therapeutic decisions in both the adjuvant and metastatic setting. The recent search for therapeutic variants is a significant molecular-genetic contribution to the framework of personalized medicine.
Editorial acknowledgement
The study was supported by Ministry of Health, Czech Republic – conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.
The funders had no role in the preparation of data, no relationship to the study.
Clinical trial identification
Legal entity responsible for the study
A. Kalfusova.
Funding
The study was supported by Ministry of Health, Czech Republic – conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203. The funders had no role in the preparation of data, no relationship to the study.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract